|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS10716 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-Phospho-PTEN(Ser380/Thr382/Thr383) |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated Synthesised phosphopeptide derived from human PTEN around the phosphorylation site of Ser380/Thr382/Thr383 |
中文名稱 磷酸化抑制基因PTEN抗體說明書
英文名稱 Anti-Phospho-PTEN(Ser380/Thr382/Thr383)
別 名 PTEN(Phospho-Ser380/Thr382/Thr383); PTEN(phospho S380/T382/Thr383); PTEN(Phospho-Ser380/Thr382/Thr383); ITGA 2; MGC11227; MHAM; MMAC 1; MMAC1; Bannayan Zonana; BZS a; Multiple hamartoma (Cowden syndrome); Mutated in Mutiple Advanced Cancers 1; Phosphatase and Tensin Homolog; Phosphatidylinositol 345 trisphosphate 3 phosphatase and dual specificity protein phosphatase PTEN; Phosphatidylinositol 345 trisphosphate 3 phosphatase; Platelet antigen BR; PTEN 1; PTEN1; Tensin homolog; TEP 1; TEP1; VLA 2 Receptor Alpha Subunit.
產(chǎn)品屬性：
磷酸化抑制基因PTEN抗體說明書 濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse
產(chǎn)品類型 一抗 磷酸化抗體
研究領(lǐng)域 細(xì)胞生物 免疫學(xué) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶
蛋白分子量 predicted molecular weight: 44kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human PTEN around the phosphorylation site of Ser380/Thr382/Thr383
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
磷酸化抑制基因PTEN抗體說明書 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Potential tumor suppressor. Acts as a phosphoinositide3-phosphatase by regulating PtdIns (3,4,5)P3 levels. Involved in regulation of the AKT1 signaling pathway. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation.The PTEN/MMAC1 discovers the first to have the suppress of the phosphoric acid enzyme activity cancer gene currently.The gene of PTEN locates the chromosome10q23 area, sending forth sex tumor and a few households cancers with the variety to suffer from the comprehensive disease easilyrelevant.The activity that passes to repress the Akt regulates the cell period, the cell ground rule decease and glues to connect.This text discussed PTEN structure, function and its correlationses, the PTEN is in tumor repress function mechanism.
Function : Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability.
Subunit : Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. Interacts with MAGI2, MAGI3, MAST1 and MAST3, but neither with MAST4 nor with DLG5. Interaction with MAGI2 increases protein stability. Interacts with NEDD4. Interacts with NDFIP1 and NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes PTEN ubiquitination. Interacts (via C2 domain) with FRK. Interacts with USP7; the interaction is direct. Interacts with ROCK1. Interacts with XIAP/BIRC4.
Subcellular Location : Cytoplasm. Nucleus. Nucleus, PML body. Note=Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization.
Post-translational modifications : Constitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2 and MAST3. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.
Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4.
DISEASE : Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD.
Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes.
Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Myhre-Smith syndrome (RMSS) or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis.
Defects in PTEN are a cause of head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
Defects in PTEN are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
Defects in PTEN are a cause of susceptibility to glioma type 2 (GLM2) [MIM:613028]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas.
[DISEASE] Defects in PTEN are a cause of VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects.
Defects in PTEN may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
Defects in PTEN are a cause of macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).
Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
Similarity : Contains 1 C2 tensin-type domain.
Contains 1 phosphatase tensin-type domain.
Database links : UniProtKB/Swiss-Prot: P60484.1
PTEN是一種抑制基因，在維持細(xì)胞的增殖、分化和凋亡平衡起重要作用，該基因在許多常表現(xiàn)為突變或雜合性丟失，NMAC1主要用于、乳腺、、非何杰金氏各種的研究.
實(shí)驗(yàn)流程：
全、新、優(yōu)、品、好四大特點(diǎn)：
磷酸化抑制基因PTEN抗體說明書 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。
新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。
優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。
好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊(duì)，產(chǎn)品一旦售出，實(shí)驗(yàn)過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時(shí)沒有任何的后顧之憂。
技術(shù)外包服務(wù):
★磷酸化抑制基因PTEN抗體說明書 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等
★蛋白工程：原核、哺乳動物蛋白表達(dá)系統(tǒng)等
★病毒包裝：腺病毒、慢病毒等
★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等
★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。
正在熱銷的相關(guān)產(chǎn)品：
Anti-CD20/MS4A1/PE 熒光素PE標(biāo)記CD20抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-Hpt/HP /FITC 熒光素標(biāo)記結(jié)合珠蛋白/觸珠蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Cdc25B 細(xì)胞分裂周期蛋白25B抗體 規(guī)格 0.1ml
ADAMTS-7(a disintegrin-like and metalloprotease-7 ) 新型金屬基質(zhì)蛋白酶(抗原) 0.5mg
IFIT1B 英文名稱： 干擾素誘導(dǎo)的三角形四肽重復(fù)蛋白1B抗體 0.2ml
Rhesus antibody Rh TDP-43 Tar DNA 結(jié)合蛋白43抗體 規(guī)格 0.1ml
Anti-Hpt/HP /FITC 熒光素標(biāo)記結(jié)合珠蛋白/觸珠蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
anti-Integrin alpha E2 /FITC 熒光素標(biāo)記整合素alpha E2 抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-Phospho-S6 Ribosomal Protein (Ser240/244) /FITC 熒光素標(biāo)記磷酸化S6核糖體蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh ANKRD26 錨蛋白重復(fù)結(jié)構(gòu)域蛋白26抗體 規(guī)格 0.2ml
Rabbit Anti-Monkey IgM/Gold 膠體金標(biāo)記的兔抗猴IgM 0.5ml
GCDGP15 英文名稱： 囊性組織液體蛋白15抗體 0.1ml
Rhesus antibody Rh Rabbit Anti-human IgG F(ab')2/Cy3 Cy3標(biāo)記的兔抗人IgG F(ab')2 規(guī)格 0.1ml
Anti-Phospho-S6 Ribosomal Protein (Ser240/244) /FITC 熒光素標(biāo)記磷酸化S6核糖體蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
HSP-27 ELISA Kit 大鼠熱休克蛋白27Multi-class antibodies規(guī)格： 48T
Anti-TRAF2 壞死因子受體相關(guān)因子2抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh GLB1L3 β半乳糖苷酶1樣蛋白3抗體 規(guī)格 0.2ml
GP- II b III a/CD41+CD61 ELISA Kit 大鼠血小板膜糖蛋白ⅡbⅢa 96T
phospho-NIPA(Ser354) 英文名稱： 磷酸化間變性激酶核相互作用伴侶蛋白抗體 0.1ml
Beta-arrestin 1 英文名稱： β-抑制蛋白1抗體 0.2ml
Anti-TRAF2 壞死因子受體相關(guān)因子2抗體Multi-class antibodies規(guī)格： 0.2ml
CL-0092HBZY-1(大鼠腎小球系膜細(xì)胞)5×106cells/瓶×2
CLEC14A Others Rat 大鼠 CLEC14A / EGFR-5 人細(xì)胞裂解液 (陽性對照)
人海馬趾神經(jīng)細(xì)胞裂解物HN-h L
Caov-3細(xì)胞，人細(xì)胞 大鼠胰島素細(xì)胞,INS-1細(xì)胞 神經(jīng)元細(xì)胞Many types of cells包裝：5 ×105次方(1ml)
Chang liver (CCL13) (人張氏肝細(xì)胞) 5×106cells/瓶×2
SkMC Pellet 人骨骼肌細(xì)胞團(tuán)塊 > 1 mio.cells 人基質(zhì)細(xì)胞cDNAHHGMC cDNA
CL-0090Hacat(人永生化角質(zhì)形成細(xì)胞)5×106cells/瓶×2
MBL2 Others Human 人 MBL2 / MBL / COLEC1 CHO細(xì)胞裂解液 (陽性對照)
人神經(jīng)細(xì)胞裂解物HNL
牛腎細(xì)胞;MDBK 人咽鱗癌細(xì)胞，F(xiàn)aDu細(xì)胞 Nb2-11細(xì)胞，小鼠細(xì)胞
EB病毒轉(zhuǎn)化的人B淋巴細(xì)胞;KM932
THSD1 Others Mouse 小鼠 THSD1 / TMTSP 人細(xì)胞裂解液 (陽性對照)
磷酸化抑制基因PTEN抗體說明書 SDC4 Others Mouse 小鼠 Syndecan-4 / SDC4 人細(xì)胞裂解液 (陽性對照)
人胚;MRC-5
HCCC-9810 人膽管細(xì)胞型細(xì)胞
293 Cells, low passage人胚腎細(xì)胞 293 Cells, low and passage in human embryo kidney cell 人胚腎細(xì)胞
LTA Protein Human 重組人 TNF-beta / TNFSF1 / Lymphotoxin alpha 蛋白
人臍帶動脈內(nèi)皮細(xì)胞 (HUAEC)( 5×105 ) A549, 人細(xì)胞系 Human
|
|
|
|
|
